Although strict control of plasma glucose is necessary for the management of diabetic nephropathy, effective treatment for massive proteinuria has not yet been established. We examined the effect of a protease inhibitor, Camostat Mesilate, on diabetic patients with massive proteinuria. Camostat Mesilate (600 mg/day) was given orally to three diabetic patients in the nephrotic stage. Urinary protein was markedly decreased after the treatment for one or two weeks in all patients and stayed at a low level for several months. It has been suggested that the inhibitory effects of Camostat Mesilate on platelet aggregation, coagulation and free radical activity improve the renal function and decrease proteinuria, but the details remain unknown. We conclude that Camostat Mesilate is useful in reducing the urinary protein excretion in some, if not all, patients with diabetic nephropathy.
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism